Note: Ingredients listed on restricted chemical lists
EC/CAS
247-500-7/55965-84-9
Name of the chemical
Mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)
Concentration
<1
EC/CAS
220-239-6
Name of the chemical
Mixture of 5-Chloro-2-methyl-isothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one 2-Methyl-2H-isothiazol-3-one
Concentration
N/A
General Information
Version
2.0
Revision date
2023-03-29
Product name
Cool FX
1.2.1 Relevant identified uses
Industrial/Professional use spec Industrial
Manufacturer Name
Lumiforte EMEA SAS
Icons in SDS
Company Information
company name
Lumiforte EMEA SAS
e-mail address of the competent person responsible for the Safety Data Sheet
safety@lumiforte.com
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Supplemental label elements
EUH208 - Contains Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [N. CE 247-500-7] and 2-methyl-2H -isothiazol-3-one [EC no. 220-239-6] (3:1) (55965-84-9). May produce an allergic reaction. EUH210 - Safety data sheet available on request.
2.3 Other hazards
Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 % Component Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [N. The mixture does not contain substance(s) included in the list established in accordance with CE 247-500-7] and 2-methyl-2H -isothiazol-3-one [EC Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as no. 220-239-6] (3:1)(55965-84-9) having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
